ABCB5 and recessive dystrophic epidermolysis bullosa: To stimulate development and marketing of ABCB5+ MSCs for the treatment of RDEB, both the US Food and Drug Administration and the European Medicines Agency have granted to ABCB5+ MSCs orphan medicinal product/drug designation, which offers several incentives including a 7-year (USA) or 10-year (EU) market exclusivity for RDEB [206,207].